|
|
|
|
|
|
|
02.04.26 - 20:42
|
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.02.26 - 14:33
|
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026 (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
